Related Experiment Video

Updated: Jan 13, 2026

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

10.7K

Renal cell carcinoma: a priority malignancy for development and study of novel therapies

Robert J Motzer

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |March 29, 2003
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    14.1K
    Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

    Published on: April 29, 2014

    17.1K

    Related Experiment Videos

    Last Updated: Jan 13, 2026

    Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
    09:28

    Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

    Published on: May 12, 2019

    10.7K
    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    14.1K
    Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

    Published on: April 29, 2014

    17.1K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    8.6K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.6K

    Articles linked to this work by shared authors, journal, and citation graph.

    Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER.

    The oncologist·2026

    Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.

    Journal for immunotherapy of cancer·2026

    Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

    The New England journal of medicine·2026

    Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

    Cancer cell·2026

    Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

    The oncologist·2026

    Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    The Patient Who Could Not Die.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us